Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Hansur L., Pawitan J.A.
57296411600;6508348067;
The potential of hydroxysafflor yellow a as an adjuvant in covid-19 patients with acute respiratory distress syndrome
2021
International Medical Journal
28
5
527
531
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Muhammadiyah Makassar, Makassar, Indonesia; Department of Histology, Faculty of Medicine, Universitas Indonesia, Indonesia; Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital/ Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Hansur, L., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Faculty of Medicine, Universitas Muhammadiyah Makassar, Makassar, Indonesia; Pawitan, J.A., Department of Histology, Faculty of Medicine, Universitas Indonesia, Indonesia, Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital/ Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Objective: To discuss the potential and molecular mechanism of Carthamus tincorius derived hydroxysafflor yellow A (HSYA) as an alternative herbal adjuvant that may regulate various signaling pathways that might be related to the regulatory effects in COVID-19 patients with ALI and ARDS. Methods: We search Web of Science, PubMed, and Scopus using keywords: Carthamus tinctorius, adjuvant, cytokine storm, COVID-19, SARS-Cov-2, acute lung injury (ALI), and Acute Respiratory Distress Syndrome (ARDS), on 11 September 2020, and 18 December 2020. Results and Discussions: In COVID-19 patients, SARS-CoV-2 replication might be associated with hyper induction of pro-in-flammatory cytokine, which is known as a cytokine storm, and may cause acute lung injury (ALI) that leads to Acute Respiratory Distress Syndrome (ARDS). Carthamus tincorius derived HSYA were used in many studies, in vivo in animal models or in vitro in cell lines and showed inhibition of multiple inflammatory pathways that were involved in ALI and ARDS, which might occur in covid-19 patients. HSYA showed pleiotropic effects in regulating cytokine levels. It regulated TNF-α, IL-1β, IL-6, IFN-β, and showed protective effect by blocking TLR4, MyD88, TRIF, IRF3, NF-κB to avoid cytokine storm and prevent tissue damage. HSYA was showed to reduce oxidative stress-mediated damage, and down-regulate inflammatory cytokines. Further, it was relatively safe when studied as an adjuvant in HIV and cancer patients. Conclusion: We supposed that HSYA could be used as an alternative adjuvant in COVID-19 patients with ARDS. However, clinical trials are needed to prove its efficacy in COVID-19 patients with ARDS. © 2021 Japan University of Health Sciences & Japan International Cultural Exchange Foundation.
Carthamus tinctorius; COVID-19; Cytokine storm; HSYA; SARS-Cov-2
adjuvant; curcumin; hydroxysafflor yellow a; interleukin 1beta; interleukin 6; interleukin 8; myeloid differentiation factor 88; natural product; pathogen associated molecular pattern; toll like receptor 4; tumor necrosis factor; unclassified drug; acute lung injury; adult respiratory distress syndrome; antiinflammatory activity; apoptosis; Article; binding affinity; brain ischemia; cancer patient; coronavirus disease 2019; cytokine production; cytokine storm; down regulation; dyspnea; endothelial dysfunction; endothelium cell; enzyme activity; human; Human immunodeficiency virus; immune response; inflammation; lung edema; nonhuman; pleiotropy; protein expression; protein function; reperfusion injury; respiratory failure; Severe acute respiratory syndrome coronavirus 2; signal transduction
Japan International Cultural Exchange Foundation
13412051
Article
Q4
183
20490